Title
Category
Credits
Event date
Cost
The Staying Power of Immunotherapies: Approaching Melanoma Care from an Inclusive Perspective
  • LivDerm
  • TME
  • 1.75 ACPE Pharmacy
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC
  • 1.75 Participation
$0.00
Melanoma can be a life-threatening condition if left untreated. Patients with skin of color often face delays in diagnosis and treatment initiation in melanoma care. These disparities point to the need for increased awareness and education on melanoma risk and identification for clinicians and patients. Immunotherapies as mono and combination therapeutic regimens have become the gold standard in melanoma management.
Webcast: Advances in Screening, Diagnosis, and Treatment of Iron Deficiency in Heart Failure Patients
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Iron deficiency (ID) with or without anemia is a common and important comorbidity in patients with heart failure (HF), and it can have significant impacts on morbidity and mortality.  Despite this burden, the diagnosis and assessment of ID is not widely sought by clinicians that see patients with HF, leading to underdiagnosis, misdiagnosis, and delayed treatment.  Recent trials and evidence have shown that i.v. iron repletion in HF patients with ID can improve symptoms, quality of life, and outcomes, and this evidence has been reflected accordingly in the updated HF guidelines.
Webcast: Challenging Cases in Patients with Iron Deficiency and Heart Failure
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
$0.00
Addressing iron deficiency (ID) in patients with heart failure (HF) has become an important aspect of optimizing guideline-directed care in HF, as outlined by recent evidence and updated guidelines. During this webinar, expert faculty utilize challenging cases to discuss the importance of addressing ID in HF, as well as practical considerations for the diagnosis and treatment of ID in this setting.
Webcast: Screening, Diagnosis and Treatment of IDA in NDD-CKD
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Iron deficiency anemia (IDA) is a common condition in patients with non–dialysis-dependent chronic kidney disease (NDD-CKD) that can affect quality of life and lead to suboptimal outcomes. Despite the impacts of IDA in NDD-CKD patients, its screening, diagnosis, and treatment remains challenging. Recent trials and evidence has shown that i.v. iron supplementation for the treatment of IDA might be beneficial in this setting, and during this webcast,, experts will discuss important advances and considerations about the screening, diagnosis, and treatment of IDA in patients with NDD-CKD.
Webcast: Challenging Cases in NDD-CKD patients with IDA
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Iron deficiency anemia (IDA) is the most common cause of anemia in patients with non–dialysis-dependent chronic kidney disease (NDD-CKD) and addressing this condition is important in the overall management of these patients. During this webcast, expert faculty utilize challenging cases to discuss important clinical pearls about the screening, diagnosis and treatment of IDA in NDD-CKD.This activity is part of the IDA in NDD-CKD Digital Education Hub.
Webcast: Challenging Cases in Lipid Lowering: Interpreting the Evidence to Patient Care
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Expert faculty developed three challenging cases that illustrate practical points about the current challenges of optimizing LDL-C lowering therapy, as well as how to optimize treatment with statin and non-statin therapies. In addition, the cases serve to offer clinical pearls on how the newer therapies fit into the treatment landscape and inform patient selection. During the webcast, expert faculty engage in interactive discussions to offer additional perspectives and clinical pearls.
Webcast: Optimizing LDL-C Management Post-MI: Patient Case & Expert Discussions
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Expert faculty developed challenging cases to illustrate practical points in the optimization of LDL-C therapy post-MI, including, but not limited to the points illustrated below. At the end of each case, faculty engage in discussions to offer clinical pearls and expert insights on the cases.
Clinical Spotlight: Pediatric Diagnosis & Treatment for Rett Syndrome
  • TME
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC
  • 1.25 Participation
$0.00
Rett Syndrome is one of the most frequent causes of mental disability in females, with an estimated prevalence of 1 in 10,000 under the age of 12. It is characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability.
Primer: Gamechangers in Alopecia Areata: Targeted Therapies for Patient-Centered Care
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Additionally, studies have uncovered risk factors for AA that clinicians need to be aware of when treating either pediatric or adult patients. 
Managing Psoriatic Arthritis Together: A Multidisciplinary Approach to Care Between Rheumatologists and Dermatologists
  • LivDerm
  • TME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Psoriatic arthritis (PsA) is a chronic, debilitating inflammatory disease that is associated with several comorbidities and often antecedes psoriasis. In fact, according to data from the National Psoriasis Foundation (NPF), approximately 30% of people with psoriasis develop PsA, with symptoms appearing around 10 years after the occurrence of cutaneous symptoms.